GlassScriptPhysician profile
Ashley B Watterson
NPI 1003181611
$5,222.29
in general payments reported to CMS, 2019-2025
26 companies · $1,883 in 2025
The $1,883 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.38 · 2022: $72.64 · 2023: $1,168 · 2024: $2,068 · 2025: $1,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,119.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,122.14 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $625.50 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $523.66 | 2023-2025 | Tremfya |
| Ucb, INC. | $489.77 | 2023-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $441.31 | 2023-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $242.56 | 2023-2025 | Siliq, Targretin, Cabtreo |
| Sun Pharmaceutical Industries INC. | $221.64 | 2023-2025 | Winlevi, Ilumya, Odomzo |
| Pfizer INC. | $207.58 | 2023-2025 | |
| Leo Pharma INC. | $176.32 | 2023-2025 | Adbry |
| Dermavant Sciences, INC. | $158.65 | 2024 | Vtama |
| Amgen INC. | $137.47 | 2023-2025 | Otezla, Otezla |
| Genzyme Corporation | $122.60 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $102.91 | 2023-2025 | |
| Incyte Corporation | $85.61 | 2023-2025 | Opzelura |
| Lilly USA, LLC | $82.58 | 2023-2024 | Taltz, Olumiant, Ebglyss |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $80.83 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $78.22 | 2024 | |
| Novo Nordisk INC | $67.08 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $64.43 | 2024 | Zoryve |
| Mallinckrodt Hospital Products INC. | $60.47 | 2024-2025 | Acthar |
| Organogenesis INC. | $41.29 | 2023-2024 | Puraply |
| Merck Sharp & Dohme LLC | $19.11 | 2021 | |
| Genentech USA, INC. | $18.93 | 2023 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.52 | 2024 | Spevigo |
| Almirall LLC | $17.28 | 2023 | Klisyri |
| Sanofi-Aventis U.S. LLC | $16.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Watterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.